Tortorici Victor, Aponte Yexica, Acevedo Humberto, Nogueira Lourdes, Vanegas Horacio
Instituto Venezolano de Investigaciones Cientificas (IVIC), Caracas, Venezuela.
Eur J Neurosci. 2009 Mar;29(6):1188-96. doi: 10.1111/j.1460-9568.2009.06678.x.
Opiate analgesia can be hampered by a reduction in pharmacological effectiveness (tolerance), and this crucially depends on the periaqueductal gray matter (PAG). Non-opioids like metamizol (dipyrone) or aspirin also induce PAG-dependent analgesia and tolerance, but the neuronal bases of this tolerance are unknown. Metamizol is a pyrazolon derivative and cyclooxygenase inhibitor with widespread use as an analgesic in Europe and Latin America. Metamizol was microinjected into the PAG of awake male rats, and antinociception was assessed by the tail flick (TF) and hot plate (HP) tests. Microinjection twice daily for 2.5 days caused tolerance to metamizol. The rats were then anesthetized and recordings from pain-facilitating on-cells and pain-inhibiting off-cells of the rostral ventromedial medulla (RVM) were performed. PAG microinjection of morphine or metamizol depresses on-cells, activates off-cells and thus inhibits nociception, including TF and HP. In metamizol-tolerant rats, however, PAG microinjection of metamizol failed to affect on- or off-cells, and this is interpreted as the reason for tolerance. In metamizol-tolerant rats morphine microinjection into PAG also failed to affect RVM neurons or nociception (cross-tolerance). In naïve, non-tolerant rats the antinociceptive effect of PAG-microinjected metamizol or morphine was blocked when CTOP, a mu-opioid antagonist, was previously microinjected into the same PAG site. These results emphasize a close relationship between opioid and non-opioid analgesic mechanisms in the PAG and show that, like morphine, tolerance to metamizol involves a failure of on- and off-cells to, respectively, disfacilitate and inhibit nociception. Cross-tolerance between non-opioid and opioid analgesics should be important in the clinical setting.
阿片类镇痛药的药理作用减弱(耐受性)会妨碍其镇痛效果,而这关键取决于导水管周围灰质(PAG)。美洛昔康(安乃近)或阿司匹林等非阿片类药物也会诱导依赖PAG的镇痛和耐受性,但这种耐受性的神经基础尚不清楚。美洛昔康是一种吡唑啉衍生物和环氧化酶抑制剂,在欧洲和拉丁美洲广泛用作镇痛药。将美洛昔康微量注射到清醒雄性大鼠的PAG中,并通过甩尾(TF)和热板(HP)试验评估抗伤害感受作用。每天两次微量注射,持续2.5天会导致对美洛昔康产生耐受性。然后将大鼠麻醉,并记录延髓头端腹内侧(RVM)的促痛性on细胞和抑痛性off细胞的活动。向PAG微量注射吗啡或美洛昔康会抑制on细胞,激活off细胞,从而抑制伤害感受,包括TF和HP。然而,在对美洛昔康耐受的大鼠中,向PAG微量注射美洛昔康未能影响on细胞或off细胞,这被解释为产生耐受性的原因。在对美洛昔康耐受的大鼠中,向PAG微量注射吗啡也未能影响RVM神经元或伤害感受(交叉耐受性)。在未接触过药物、无耐受性的大鼠中,当μ阿片受体拮抗剂CTOP预先微量注射到相同的PAG部位时,PAG微量注射美洛昔康或吗啡的抗伤害感受作用会被阻断。这些结果强调了PAG中阿片类和非阿片类镇痛机制之间的密切关系,并表明,与吗啡一样,对美洛昔康的耐受性涉及on细胞和off细胞分别无法促进和抑制伤害感受。非阿片类和阿片类镇痛药之间的交叉耐受性在临床环境中应该很重要。